Research output per year
Research output per year
Research output
- 13 results
Search results
-
2024
Clonal evolution and blastic plasmacytoid dendritic cell neoplasm: malignancies of divergent hematopoietic lineages emerging from a common founding clone
Denker, S., Künstner, A., Schwarting, J., Witte, H. M., Bernard, V., Stölting, S., Lohneis, P., Kusch, K., von Bubnoff, N., Merz, H., Busch, H., Feller, A. C. & Gebauer, N., 08.2024, In: Leukemia. 38, 8, p. 1858-1861 4 p.Research output: Journal Articles › Letters › peer-review
-
2020
Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT
Shoumariyeh, K., Hussung, S., Niemöller, C., Bleul, S., Veratti, P., Follo, M., Riba, J., Philipp, U., Palmer, J. M., Pfeifer, D., Pantic, M., Meggendorfer, M., Hackanson, B., Finke, J., Haferlach, T., Duyster, J., Miething, C., Becker, H. & von Bubnoff, N., 01.09.2020, In: British Journal of Haematology. 190, 6, p. e339-e343Research output: Journal Articles › Letters › peer-review
-
Ruxolitinib for Acute Graft-versus-Host Disease. Reply
Zeiser, R., von Bubnoff, N. & Socié, G., 30.07.2020, In: The New England journal of medicine. 383, 5Research output: Journal Articles › Letters › peer-review
-
2013
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
Sigl, M., Spoerl, S., Schnittger, S., Meissner, J., Rummelt, C., Peschel, C., Duyster, J., Ho, A. D. & Von Bubnoff, N., 03.2013, In: Blood Cancer Journal. 3, 3, e104.Research output: Journal Articles › Letters › peer-review
1 Citation (Scopus) -
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD + AML but retains in vitro sensitivity to PKC412 and Sunitinib
Albers, C., Leischner, H., Verbeek, M., Yu, C., Illert, A. L., Peschel, C., Von Bubnoff, N. & Duyster, J., 06.2013, In: Leukemia. 27, 6, p. 1416-1418 3 p.Research output: Journal Articles › Letters › peer-review
39 Citations (Scopus) -
2010
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib
Von Bubnoff, N., Rummelt, C., Menzel, H., Sigl, M., Peschel, C. & Duyster, J., 08.2010, In: Leukemia. 24, 8, p. 1523-1525 3 p.Research output: Journal Articles › Letters › peer-review
12 Citations (Scopus) -
2008
Interleukin-10 (-819 C/T) and TNF-A (-308 G/A) as risk factors for H. pylori-associated gastric MALT-lymphoma
Hellmig, S., Bartscht, T., Fischbach, W., Fölsch, U. R. & Schreiber, S., 07.2008, In: Digestive Diseases and Sciences. 53, 7, p. 2007-2008 2 p.Research output: Journal Articles › Letters › peer-review
4 Citations (Scopus) -
2007
Subcutaneous nodules revealing acute monoblastic leukaemia (FAB type M5A) [34]
Athanasiadis, G. I., Pfab, F., Braun-Falco, M., von Bubnoff, N., Fend, F., Ring, J. & Ollert, M., 10.2007, In: Journal of the European Academy of Dermatology and Venereology. 21, 9, p. 1296-1297 2 p.Research output: Journal Articles › Letters › peer-review
1 Citation (Scopus) -
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib [1]
Menzel, H., von Bubnoff, N., Hochhaus, A., Haferlach, C., Peschel, C. & Duyster, J., 07.2007, In: Bone Marrow Transplantation. 40, 1, p. 83-84 2 p.Research output: Journal Articles › Letters › peer-review
11 Citations (Scopus) -
2006
The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib) [4]
Von Bubnoff, N., Gorantla, S. P., Thöne, S., Peschel, C. & Duyster, J., 15.06.2006, In: Blood. 107, 12, p. 4970-4971 2 p.Research output: Journal Articles › Letters › peer-review
54 Citations (Scopus) -
2005
Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib [1]
Dengler, J., von Bubnoff, N., Decker, T., Peschel, C. & Duyster, J., 10.2005, In: Leukemia. 19, 10, p. 1835-1838 4 p.Research output: Journal Articles › Letters › peer-review
20 Citations (Scopus) -
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia [1]
von Bubnoff, N., Sandherr, M., Schlimok, G., Andreesen, R., Peschel, C. & Duyster, J., 02.2005, In: Leukemia. 19, 2, p. 286-287 2 p.Research output: Journal Articles › Letters › peer-review
89 Citations (Scopus) -
The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 [1]
von Bubnoff, N., Gorantla, S. H. P., Kancha, R. K., Lordick, F., Peschel, C. & Duyster, J., 09.2005, In: Leukemia. 19, 9, p. 1670-1671 2 p.Research output: Journal Articles › Letters › peer-review
63 Citations (Scopus)